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Women with germ-line mutations of the BRCA1 tumor suppressor
gene are highly susceptible to breast and ovarian cancer. The
protein product of BRCA1 is involved in a broad spectrum of
biological processes and interacts with many diverse proteins. One
of these, BARD1, associates with BRCA1 to form a heterodimeric
complex that is enzymatically active as an ubiquitin E3 ligase.
Although the BRCA1/BARD1 heterodimer has been implicated in
several aspects of BRCA1 function, its role in tumor suppression has
not been evaluated. To address this question, we generatedmouse
strains carrying conditional alleles of either Bard1 or Brca1 and
used Cre recombination to inactivate these genes in mammary
epithelial cells. Significantly, the conditional Bard1- and Brca1-
mutant mice developed breast carcinomas that are indistinguish-
able from each other (and from those of double conditional
Bard1/Brca1-mutant animals) with respect to their frequency, la-
tency, histopathology, and cytogenetic features. Reminiscent of
the basal-like breast carcinomas seen in human BRCA1 mutation
carriers, these tumors are ‘‘triple negative’’ for estrogen and
progesterone receptor expression and HER2/neu amplification.
They also express basal cytokeratins CK5 and CK14, have an
elevated frequency of p53 lesions, and display high levels of
chromosomal instability. The remarkable similarities between the
mammary carcinomas of Bard1-, Brca1-, and Bard1/Brca1-mutant
mice indicate that the tumor suppressor activities of both genes are
mediated through the BRCA1/BARD1 heterodimer.
basal-like breast cancer  mammary carcinogenesis
Germ-line mutations of the BRCA1 tumor suppressor geneserve as predisposing lesions in women with a familial suscep-
tibility to breast and ovarian cancer (1). The breast tumors of
BRCA1mutation carriers typically display ‘‘basal-like’’ features that
define a subtype of breast cancer with a distinct histopathology and
gene expression profile (2–5). Basal-like breast carcinomas have
been described as ‘‘triple negative’’ because they often lack expres-
sion of estrogen receptor (ER) , the progesterone receptor (PR),
and the HER2/neu protooncogene. Patients with basal-like breast
cancer face a poor prognosis and reap little benefit from current
therapies that target ER- or HER2-expressing tumor cells.
Although the mechanism of BRCA1-mediated tumor suppres-
sion is unclear, its protein product has been implicated in a
remarkably broad range of cellular processes, some of which serve
to maintain genome stability (6–8). Consistent with its pleiotropic
nature, the BRCA1 polypeptide has been reported to interact with
a large and diverse group of proteins. One of these, BARD1, is
structurally related to BRCA1 in that it harbors an N-terminal
RING motif and two C-terminal BRCT domains (9), and the
heterodimer complex formed by these proteins functions as a
potent ubiquitin E3 ligase (10). Although it has been proposed that
the tumor suppression activity of BRCA1 is mediated by the
BRCA1/BARD1 heterodimer (11), experimental evidence to sup-
port this hypothesis is lacking.
Early attempts to develop animal models of BRCA1-linked
breast cancer were unsuccessful (reviewed in ref. 12). Tumor
formation was not observed in heterozygous mice bearing null or
hypomorphic Brca1 alleles, whereas early embryonic lethality pre-
cluded tumor development inBrca1 nullizygousmice.Nevertheless,
homozygous mice with certain hypomorphic Brca1 alleles can
survive to adulthood, on which they display heightened suscepti-
bility to a range of tumors, including mammary carcinomas (13). In
addition, tumors can also be induced by conditional inactivation of
Brca1 in breast epithelial cells through cre/loxP-mediated recom-
bination (14), and recent studies show that the mammary tumors
generated by conditional Brca1 inactivation resemble the basal-like
breast tumors of human BRCA1 mutation carriers (15, 16).
Although many BRCA1 functions are executed by the BRCA1/
BARD1heterodimer, the role of this complex in BRCA1-mediated
tumor suppression has not been tested. If the heterodimer is
required for tumor suppression, one would expect that BARD1
deficiency, in either clinical or experimental settings, would pro-
mote the formation of tumors that resemble those arising in
BRCA1 mutation carriers. Tumor-specific lesions of BARD1 have
been observed in human cancers, including breast and ovarian
carcinomas (17–19), and although thesemutations are rare, they are
often associatedwith tumor-specific loss of the other BARD1 allele
(18). Nevertheless, unlike the cancer-predisposing lesions of
BRCA1, which are mostly frameshift or nonsense mutations that
grossly disrupt its protein coding potential, the known tumor-
specific lesions of BARD1 are all missense mutations (17–19). To
test the tumor suppression potential of BARD1 experimentally, we
have generated mouse strains that undergo mammary-specific
inactivation of the Bard1 and/or Brca1 genes. Analysis of these
strains revealed that conditional inactivation of Bard1 induces
basal-like mammary carcinomas with a frequency, latency, and
histopathology that are indistinguishable from those that develop in
conditional Brca1-mutant mice and double conditional Bard1/
Brca1-mutant mice. These results establish that BARD1 is itself a
tumor suppression gene and that BRCA1-mediated tumor suppres-
sion is mediated by the BRCA1/BARD1 heterodimer.
Results
Mammary-Specific Inactivation of Bard1 and Brca1. Because the
tumor suppressor activity of BRCA1 can be demonstrated exper-
Author contributions: R.S. and T.L. designed research; R.S., E.M., and E.O. performed
research; K.B. and S.N. contributed new reagents/analytic tools; R.S., M.S., E.M., E.O., K.B.,
S.N., V.M., R.B., and T.L. analyzed data; and R.S., M.S., V.M., R.B., and T.L. wrote the paper.
The authors declare no conflict of interest.
This article is a PNAS Direct Submission.
Freely available online through the PNAS open access option.
*To whom correspondence should be addressed. E-mail: tl54@columbia.edu.
This article contains supporting information online at www.pnas.org/cgi/content/full/
0711032105/DCSupplemental.
© 2008 by The National Academy of Sciences of the USA
7040–7045  PNAS  May 13, 2008  vol. 105  no. 19 www.pnas.orgcgidoi10.1073pnas.0711032105
imentally by disrupting the mouse Brca1 gene (13–16), we used a
similar strategy to ascertain whether BARD1 also functions as a
tumor suppressor. To bypass the embryonic lethality of Bard1
nullizygous (Bard1/) mice (20), a conditional Bard1 allele
(Bard1flex1) was generated by homologous recombination in ES
cells. Two loxP sites were positioned within theBard1flex1 allele such
that a DNA fragment encompassing the promoter (2 kbp of 5
flanking sequence) and exon 1 (which encodes the initiator methi-
onine and part of the RING domain) of the Bard1 gene would be
deleted on Cre-mediated recombination [supporting information
(SI) Fig. S1]. To compare the consequences of mammary-specific
ablation of Bard1 and Brca1, we also generated a conditional Brca1
allele by flanking exon 2, which encodesmost of theRINGdomain,
with loxP sites (Fig. S2). In contrast to the early embryonic lethality
of Bard1- and Brca1-nullizygous embryos (20), homozygous
Bard1flex1/flex1 and Brca1flex2/flex2mice are healthy, fertile, and have a
normal lifespan, indicating that the loxP sites of the conditional
Bard1flex1 and Brca1flex2 alleles do not interfere with normal func-
tion of these genes. To assess the functions of the Cre-recombined
products of the conditional alleles (i.e., Bard1flex1 and Brca1flex2),
Bard1flex1/flex1 and Brcaflex2/flex2 mice were mated, respectively, with
Bard1/ and Brca1/ animals that carry a ubiquitously expressed
cre transgene (Hscre) driven by the mouse Hsp70-1 gene promoter
(21). Notably, the Bard1flex1//Hscre and Brca1flex2//Hscre off-
spring of these crosses suffered an early embryonic lethality (data
not shown) similar to that of nullizygous (i.e.,Bard1/ orBrca1/)
mice. These results indicate that the Bard1flex1 and Brca1flex2
alleles that arise, respectively, on Cre-mediated recombination of
Bard1flex1 and Brca1flex2 are nonfunctional.
To inactivate the conditional alleles in mammary glands,
Bard1flex1/flex1 andBrca1flex2/flex2 animalswere crossedwithBard1/,
Brca1/, andWapcre/ knockin mice that express cre under control
of regulatory elements from the whey acidic protein (Wap) gene,
expression of which is restricted to mammary epithelial cells during
late pregnancy and lactation (22). These crosses, and additional
crosses of the relevant progeny, generated conditional Bard1
(Bard1flex1/flex1/Wapcre/ and Bard1flex1//Wapcre/) and Brca1
(Brca1flex2/flex2/Wapcre/ and Brca1flex2//Wapcre/) females, all of
whom appeared normal in that they were fertile, had normal litter
sizes, and were able to nurse their pups.
Mammary Tumor Development in Conditional Bard1, Brca1, and Bard1/
Brca1 Females. Experimental cohorts of conditional Bard1 (n 16;
10 Bard1flex1/flex1/Wapcre/ and 6 Bard1flex1//Wapcre/) and condi-
tional Brca1 (n  33; 20 Brca1flex2/flex2/Wapcre/ and 13 Brca1flex2//
Wapcre/) females were mated to induce at least one round of
pregnancy and lactation, and then monitored for tumor formation.
As shown inFig. 1,mammary tumors developedwith high incidence
and long latency in the experimental cohorts, whereas all control
animals [Bard1flex1//Wapcre/ (n  10) and Brca1flex2//Wapcre/
(n  11)] remained tumor-free over the entire observation period
(data not shown). A total of 21 mammary tumors developed in 15
of 16 conditional Bard1/Wapcre/ females with a median tumor-free
survival (T50) of 465 days (Fig. 1). Notably, 35 tumors appeared in
31 of 33 conditional Brca1/Wapcre/ females with a latency (T50 
512 days) that is statistically indistinguishable from that of the
Bard1/Wapcre/ mice (P  0.1977, log-rank test) (Fig. 1). Southern
blot analysis confirmed that the conditionalBard1 andBrca1 alleles
were recombined in these mammary tumors (Figs. S1C and S2C).
To examine the consequences of concomitant inactivation of
Bard1 and Brca1, we also monitored a cohort of double conditional
Bard1flex1/flex1/Brca1flex2/flex2/Wapcre/ females and observed 18 tu-
mors develop in 11 of 13 experimental females with a T50 of 473
days. As shown in Fig. 1, the survival curves of the three experi-
mental cohorts are overlapping and statistically indistinguishable
(P  0.2660, log-rank test with df  2). Furthermore, all pairwise
comparisons of the cohort survival curves yielded statistically
insignificant results (Bard1 vs. Brca1, P  0.1977; Bard1 vs. Bard1/
Brca1, P  0.8643; and Brca1 vs. Bard1/Brca1, P  0.1479),
indicating that the mutant alleles of these genes are epistatic with
respect to mammary carcinogenesis. These results support the
hypothesis that Bard1 and Brca1 promote tumor suppression
through common genetic/biochemical pathways.
The Basal-Like Phenotype of Bard1-, Brca1-, and Bard1/Brca1-Mutant
Mammary Tumors. The mammary tumors of the conditional Bard1
and conditional Brca1 females were invasive adenocarcinomas that
formed bulky, round, solid nests and invaded with a broad front the
surrounding fat and underlying pectoral muscle (Fig. 2 B and D).
These solid cancer nodules were separated by highly vascular but
delicate stroma, and each contained densely packed syncytial-
appearing tumor cells. No lymphocytic infiltrate was seen along the
border of the neoplasms. Residual ductal/tubular differentiation
was consistently identified, but it constituted the dominant pattern
(75%) in only 14.3 or 8.6% of the Bard1- or Brca1-mutant
malignancies, respectively (Table 1). Both Bard1- and Brca1-
deficient cancer cells were strikingly similar, with irregularly shaped
nuclei that featured coarsely granular chromatin and conspicuous
eosinophilic nucleoli (Fig. 2 B and D, Insets). Mitotic figures were
abundant and often atypical with distorted and/or multipolar
spindles. The majority of the Bard1- or Brca1-mutant tumors were
Dunn type B adenocarcinomas with a medullary growth pattern
that displayed variable necrosis and lacked peripheral lymphocytic
infiltrate. As such, these tumors were highly reminiscent of the
human atypical medullary carcinomas that are prevalent in human
BRCA1 mutation carriers (2). Sarcomatous, adenoid-cystic, and
myoepithelial histological patterns, which are also considered to be
basaloid in human neoplasms, were not observed in the mammary
tumors of these cohorts. However, metaplastic cancers with squa-
mous differentiation occurred in 4 of 21 Bard1-mutant and 8 of 35
Brca1-mutant carcinomas, although the squamous component was
never the dominant histological architecture.
Murine intraepithelial neoplasia (MIN) was detected both adja-
cent and distal to each invasive carcinoma examined, and within
separate mammary glands, suggesting that multiple MIN foci
developed in each mouse and that one or a few of these foci
progressed to invasive carcinoma. The distinction between in situ vs.
invasive lesions was aided by immunostaining for p63, which
highlights the myoepithelial layer (data not shown). MIN consis-
tently presented as a solid growth of large highly pleomorphic cells
in both the lobuloalveolar unit and the extralobular breast ducts
(Fig. 2A andC). Because central necrosis was commonly observed,
this formofMIN is comparable with the solid and comedo subtypes
of human ductal carcinoma in situ.
By immunohistochemistry, most Bard1-mutant (19 of 21) (Fig. 3
B and C) and Brca1-mutant (34 of 35) (Fig. 3 F and G) invasive
neoplasms stained for the cytoskeletal markers of basal-like breast
Fig. 1. Survival curves of conditional Bard1, Brca1, and Bard1/Brca1 mutant
mice. Kaplan–Meier curves of tumor-free survival for conditional Bard1/
Wapcre/ (n 16), conditional Brca1/Wapcre/ (n 33), and double conditional
Brca1/Bard1/Wapcre/ (n  13) animals. The differences between the tumor-
free survivals of the three experimental cohorts are statistically insignificant.
For each cohort, the median tumor-free survival (T50) is shown in days.











cancer, including CK5 (data not shown), CK14, and vimentin
(Table 1). Vimentin is also a marker of the epithelial to mesen-
chymal transition. However, as is typical for epithelial rather than
mesenchymal cells, all Bard1- and Brca1-mutant murine breast
cancers retained E-cadherin staining along the cell surface, includ-
ing cells at the invasive front (data not shown). Although staining
for ER was readily observed in the normal epithelial cells of
adjacent or entrapped glands (Fig. 3E), most Bard1-mutant (19 of
21) (Fig. 3A) and Brca1-mutant (30 of 35) (Fig. 3E) invasive
neoplasms were ER-negative (Table 1). In addition, none of the
tumors of either genotype stained positive for PR (both  and )
(data not shown). Interestingly, high-grade MIN was also usually
negative for both ER and PR. In addition, none of the tumors
analyzed showedHER2/neu amplification as determined by South-
ern analysis of tumor DNA compared to tail DNA from the same
animal (R.S. and T.L., unpublished data). Applying a stringent
definition of the basal-like phenotype that includes positive staining
for both CK5 and -14, negative expression of both ER and PR, and
the absence of HER2/neu gene amplification, 90.5 and 85.7% of
Bard1- and Brca1-mutant mammary tumors, respectively, were
categorized as basal-like breast carcinomas.
On coinactivation of Bard1 and Brca1, the double conditional
mice developed invasive adenocarcinomas (Figs. 2 E and F and 3
I–L) similar to those seen in the single conditional Bard1- and
Brca1-mutant animals (Figs. 2 A–D and 3 A–H). All of the
Bard1/Brca1-mutant tumors analyzed were ‘‘triple negative’’ for ER
(Fig. 3I), PR, and HER2/neu gene amplification (R.S. and T.L.,
unpublished data), and most stained positive for CK5, CK14, and
vimentin (Fig. 3 J and K and Table 1). Thus, according to the
aforementioned definition of basal-like breast cancer, 77.8% of
Bard1/Brca1-mutant tumors were classified as basal-like carcino-




Fig. 2. Histological analysis of mammary tumors. H&E-stained sections of
Bard1-mutant (A and B), Brca1-mutant (C and D), and Bard1/Brca1-double-
mutant (E and F) mammary carcinomas display virtually identical pathohisto-
logical characteristics. MIN (A, C, and E), which probably arose from lobuloal-
veolar units (LA), commonly extended into extralobular breast ducts (ED).
Invasive carcinomas (B, D, and F) were composed of large solid nests of
markedly pleomorphic cells with numerous mitotic figures including tripolar
mitotic figures and those with lagging chromosomes (B, D, and F, Insets,
arrows). Such neoplasms invaded along a broad front and pushed toward the
underlying pectoral muscle (M). (Original magnification: A–F, 200; Insets,
2,000.)








CK14* ER-negative†Tubular Solid Squamous
Bard1 15 21 3 (14.3%) 18 (85.7%) 4 (19.1%) 19/21 (90.5%) 19/21 (90.5%)
Brca1 31 35 3 (8.6%) 32 (91.4%) 8 (22.9%) 34/35 (97.1%) 30/35 (85.7%)
Bard1/Brca1 11 18 4 (22.2%) 14 (77.8%) 2 (11.1%) 14/18 (77.8%) 18/18 (100%)
*At least 15% of cancer cells had to be positive for CK14 for a neoplasm to be considered to have basaloid features.
†Neoplasms were considered to be negative for ER only when 	5% of tumor cells stained positive.
Fig. 3. The immunohistochemical phenotypes of mammary carcinomas. The
Bard1- (A–D), Brca1- (E–H), or Bard1/Brca1- (I–L) mutantmammary carcinomas
shared a common basal-like phenotype that included negative staining for
estrogen receptor (ER) (A, E, and I) when compared to entrapped nonneo-
plastic mammary epithelial (E, arrow), and strong immunolabeling for vimen-
tin (B, F, and J) and CK14 (C, G, and K). Note CK14 immunolabeling is already
present in theMIN (C, Inset). Nuclear p53 immunostainingwas often detected
in the tumors (D, H, and L) and MIN (D, Inset), and correlated well with the
presence of p53 missense mutations (see Table S2).
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appearing in both lobuloalveolar units (LA) and extralobular breast
ducts, and featured a solid or comedo-type growth pattern (Fig.
2E). In summary, the histopathologic and immunohistochemical
analyses indicate that the tumors arising on conditional inactivation
of theBard1,Brca1, orBard1/Brca1 genes inmice exhibit an atypical
medullary phenotype strongly reminiscent of the basal-like breast
tumors that arise in human BRCA1 mutation carriers.
p53 Lesions in Bard1-Mutant Mammary Tumors. Relative to other
subtypes of human breast cancer, lesions of the p53 gene are
especially prevalent in basal-like tumors, including those of BRCA1
mutation carriers (23, 24). By immunohistochemistry, we observed
strong p53 nuclear staining in themajority of cancer cells from 70%
(7 of 10) of the Bard1-mutant, 78% (7 of 9) of the Brca1-mutant,
and 67% (8 of 12) of the double Bard1/Brca1-mutant mammary
carcinomas examined (Fig. 3). To evaluate the pattern of p53
mutation in Bard1-mutant mammary carcinomas, p53 exons 2–11
were PCR amplified and subjected to DNA sequence analysis
(Table S1). Six of the 10 Bard1-mutant tumors (60%) harbored
detectable p53 gene mutations, and in each of these six tumors the
wild-type p53 allele was lost. Four of the six mutations led to amino
acid substitutions (Y217D, M234I, R270H, and C272F) that re-
sulted in nuclear p53 immunostaining. The two remaining p53
mutations did not result in p53 immunostaining: aG331Wmissense
mutation and a 46-bpdeletionwithin exon 6 that causes a frameshift
and premature termination. Interestingly, the amino acid altered by
the R270H mutation corresponds to a mutation hot spot in the
human p53 sequence (human residue R273), and this same
residue was also found to be mutated in two of the Brca1-mutant
tumors (data not shown) and a reported Brca2-deficient mouse
mammary tumor (22).
Of note, MIN foci that lie adjacent to invasive breast carcinomas
frequently displayed the same p53 labeling properties as the inva-
sive carcinoma. For example, immunostaining of a tumorous mam-
mary gland from a conditional Bard1-mutant mouse (Fig. 3D Inset)
showed comparable levels of p53 overexpression in malignant cells
harboring a p53 mutation (R270H) and in the cells of an adjacent
MIN lesion. This observation supports the hypothesis that p53
mutations can manifest early in Bard1- and/or Brca1-deficient
tumor cells and that inactivation of p53 checkpoint function can be
a critical step in tumorigenesis (25).
Chromosomal Instability in Bard1- and Brca1-Mutant Tumor Cells.
Although abnormalities of chromosome number and structure
are prevalent in breast cancer, early work established that
chromosomal instability is especially severe in the tumors of
BRCA1mutation carriers (26) and that cultured tumor cells from
mouse mammary carcinomas induced by Brca1 inactivation have
elevated levels of chromosome instability (14, 27). To determine
whether Bard1-mutant mammary tumors display a similar pat-
tern of chromosomal instability, cell lines were derived from
mammary tumors of conditional Bard1-mutant and Brca1-
mutant female mice, and early passage (2–6) cultures of these
lines were examined by spectral karyotyping (SKY). Each of the
three Bard1-mutant mammary tumor lines displayed a triploid
(3N; 58–66 chromosomes) karyotype with complex structural
rearrangements (Fig. 4A). In accord with previous studies (14,
27), a similar array of numerical and structural lesions was
observed in cultured cells from three independent mammary
carcinomas that arose in conditional Brca1/Wapcre/ animals
(Fig. 4B). To assess the extent of genomic instability, we calcu-
lated an index of chromosome instability (CIN) based on the
number of chromosome breaks per haploid genome and found
a similar range of CIN ratios in the Bard1-mutant (41–74 breaks
per haploid genome) and Brca1-mutant (35–67 breaks per
haploid genome) carcinoma cells (Table S2). To determine
whether this high level of CIN is unique to Bard1- and Brca1-
mutant mammary carcinomas, we also examined cells of mam-
mary tumors derived on breast-specific inactivation of the p53
gene (in p53flex7/flex7/Wapcre/ mice, to be described elsewhere).
Although the p53-mutant tumors displayed extensive aneu-
ploidy, with chromosome numbers in the range of 3N–6N (Table
S2), very few structural chromosome aberrations were observed
(Fig. 4C). Thus, the CIN indices of the p53-mutant tumors were
nearly 10-fold lower than those seen in the Bard1- and Brca1-
mutant mammary carcinomas (Table S2).
Discussion
BRCA1 has been implicated in a remarkably diverse array of
cellular processes, many of which serve in some capacity to preserve
genome integrity. Its pleiotropic nature is consistent with biochem-
ical evidence that BRCA1 can interact withmany different proteins
and, as an ubiquitin E3 ligase, can potentially catalyze covalent
modification of these proteins. Thus, it will be important to define
which of the various BRCA1 functions, or which combinations of
these functions, are required for tumor suppression—especially in
those settings, such as mammary and ovarian epithelial cells, that
are relevant to human disease. Previous studies have shown that
conditional disruption of the mouse Brca1 gene induces mammary
carcinomas that resemble the basal-like breast tumors of human
BRCA1mutation carriers (14–16). Here, we report that conditional
inactivation of Bard1, the heterodimeric partner of Brca1, elicits
basal-like mammary tumors in mice that are indistinguishable from
those that arise on Brca1 inactivation. These results establish that
BARD1 is itself a tumor suppressor.More significantly, the striking
similarities between the Brca1- and Bard1-mutant mammary car-
cinomas indicate that the tumor suppressor functions of both
proteins are mediated by the BRCA1/BARD1 heterodimer.
A major challenge of cancer modeling is to generate experimen-
tal tumors that recapitulate both the responsible genetic lesion(s)
and consequent neoplastic phenotype of the relevant human ma-
lignancy. The mammary carcinomas of the Bard1-mice, like those
of Brca1-mutant mice, are highly reminiscent of the basal-like
atypical medullary breast tumors that arise in human BRCA1
mutation carriers. Thus, the Bard1-mutant tumors are ‘‘triple
negative’’ in that they lack expression of the estrogen and proges-
terone receptors and show no signs of HER2/neu gene amplifica-
tion. They also express basal cytokeratins CK5 and CK14, have an
elevated frequency of p53 lesions, and display extensive chromo-
somal instability. Interestingly, although all mammary tumors in-
duced by conditional inactivation of Bard1, Brca1, and p53 were
aneuploid, elevated levels of chromosomal breaks were only ob-
served in the Bard1- and Brca1-mutant tumors (Table S2), perhaps
reflecting the known requirements for BRCA1 and BARD1 in
double-strand DNA break repair (28–31).
Our data demonstrate that BARD1, like BRCA1, is a tumor
suppressor that normally functions to inhibit neoplastic transfor-
mation in mammary epithelial cells. As such, the tumor-specific
BARD1 mutations observed in patients with breast, ovarian, and
endometrial carcinomas may be oncogenic lesions that disrupt
BRCA1/BARD1-mediated tumor suppression. However, it should
be noted that the Bard1 defect induced in ourmousemodel is a null
mutation, whereas all of the BARD1 lesions reported to date in
human tumors are missense mutations (17–19). Thus, further
studies are required to ascertain whether these human BARD1
missense mutations are truly oncogenic.
The existing biochemical and cellular data are consistent with the
conclusion that BRCA1 and BARD1 polypeptides function in vivo
as an obligate heterodimer (11). Coimmunoprecipitation studies in
mammalian cells andXenopus egg extracts indicate that most, if not
all, of the cellular pool of endogenous BRCA1 exists in complex
with BARD1 (32, 33). Moreover, the two proteins remain associ-
ated as a heterodimer and colocalize within common nuclear
structures both before and after genotoxic stress (34, 35), and their
steady-state levels fluctuate in parallel during cell cycle progression
(36). Significantly, homozygous mice bearing null alleles of either











Brca1 or Bard1 display phenotypes that appear to be indistinguish-
able from one another, and from that of double Brca1/Bard1
nullizygous animals (20). In particular, these mice become devel-
opmentally retarded and die before gastrulation [between embry-
onic day 7.5 (E7.5) and E8.5] from a severe defect in cell prolif-
eration that is at least partly p53 dependent. Likewise,
indistinguishable phenotypes have also been described for nema-
todes bearing mutations in the Caenorhabditis elegans orthologs of
BRCA1 and BARD1 (37), and for plants harboring mutations in
the corresponding genes of Arabidopsis thaliana (38). Although it
has been proposed that BARD1 executes cellular functions that are
independent of BRCA1 (39), the impact of these on the phenotypes
of BARD1 mutant organisms has not yet been discerned (20, 37,
38). In any event, the data presented here suggest that BRCA1-
Fig. 4. Karyotype analysis of primary mammary carcinoma cells. Chromosomal instability identified by spectral karyotype analysis in Bard1-, Brca1-, and
p53-mutant mammary tumor cells. (A) Mutant Bard1 tumor cell line. The left image shows spectral classification of a metaphase exhibiting high frequency of
multiple complex structural chromosome abnormalities. The right image showing spectral-based display color (Upper) and the corresponding DAPI image in
black and white (Lower) of partial metaphases exhibiting various chromosomal abnormalities. The most visible abnormalities are indicated on DAPI-stained
images. (Left) a, Translocations involving two different chromosomes; b, formation of metacentric chromosome involving centromeres of two different
chromosomes; c, dicentric chromosome involving translocation of two chromosomes; d, dicentric chromosome formation by intrachromosomal rearrangement;
e, acentric chromosome. (Center) a, A large marker chromosome with multiple centromeres involving four different chromosomes. (Right) a, Tricentric
chromosome involving translocation of five different chromosomes; b, duplication of centromeric region of chromosome 18; c, translocation involving
two chromosomes. (B) Mutant Brca1 tumor cell line. The left and right images are as in A. (Left) a–d, Translocations involving two (a and d), three (c), and four
(b) chromosomes; e and f, centromere duplication; g, dicentric formation due to telomeric fusion. (Center) Chromosome translocations involving two (b–e and
g) and three (a and f) chromosomes. (Right) a, Formation of a dicentric chromosome involving three different chromosomes; b–f, simple chromosome
translocations involving two chromosomes. (C) A hyper-triploid SKY karyotype of a tumor derived bymammary gland specific inactivation of p53. Note very few
chromosomal translocations are seen in these tumors. Translocation partners are indicated.
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independent functions of BARD1, if they exist, are not required for
tumor suppression in mammary epithelial cells.
Given the diverse functions attributed to BRCA1, it will be
intriguing to know whether all or only some of these are dependent
on theBRCA1/BARD1heterodimer. Because the latency of tumor
formation in the double conditional Bard1/Brca1-mutant mice is
statistically indistinguishable from those of the single conditional
Bard1- and Brca1-mutant animals (Fig. 1), the Bard1 and Brca1
genes appear to be fully epistatic with respect to tumor suppression
in mammary epithelial cells. This observation, together with the
common phenotype of the Brca1- and Bard1-mutant tumors,
strongly suggests that the tumor suppression activities of both
proteins are mediated through the BRCA1/BARD1 heterodimer.
As an E3 ligase, the heterodimer has the potential to modulate
multiple downstream pathways by ubiquitin conjugation of itself
and other substrates. It is also conceivable that BRCA1/BARD1
has functions relevant to tumor suppression that are independent of
its E3 ligase activity. Future studies should resolve whether the
enzymatic activity of the BRCA1/BARD1 heterodimer is required
for tumor suppression and identify which of its diverse functions
serve to inhibit human carcinogenesis.
Materials and Methods
Targeted Mutagenesis. The conditional Bard1 targeting vector consisted of a
7.4-kb fragment containing the 5 flanking region and exon 1. The loxP-flanked
PGK-neo cassettewas inserted 2 kbupstreamof the transcriptional initiation site
and a single loxP site was introduced in intron 1. The conditional Brca1 vector
consisted of a 6.1-kb fragment containing exons 1 and 2. A FRT-flanked PGK-neo
cassettetogetherwithasingle loxP sitewascloned into intron1andasecond loxP
site was introduced in intron 2. Gene targeting in 129Sv ES cells and blastocyst
injections were performed following standard techniques.
Mouse Breeding. Experiments involving mice were performed according to
Columbia University Institutional Animal Care and Use Committee-approved
protocols. All of the mice used in the breeding program were on a mixed
background of 129/Sv C57BL/6J.
Molecular Analysis. For genotyping by Southern blot analysis, genomicDNAwas
preparedfromtails andmammary tumorsofmice (fordetails, seeFigs. S1andS2).
For mutational analysis of p53 in the mammary tumors, exons 2–11 were ampli-
fiedwith intron-specific primers by usingmammary tumorDNAas template and
PCR products were directly sequenced.
Histological Analysis.Mice were killed 2 weeks after mammary neoplasms were
detected by palpation and tissues were processed for histopathological evalua-
tion and immunohistochemistry. Both in situ and invasive neoplasms were eval-
uated for their growth pattern, distribution, cellular and nuclear morphology,
and mitotic rate. For immunophenotyping, all specimens were labeled with
antibodies against p63 and E-cadherin (both BD Pharmingen), vimentin (RDI),
CK5 and CK14 (both Covance), ER (Santa Cruz), PR (ABR), and p53 (Vector
Laboratories).
Cytogenetic Analysis.Metaphase preparations were made from logarithmically
growing tumor cells. Hybridization and detection of SKY probes was performed
following manufacturer’s protocol (Applied Spectral Imaging). DAPI-counter-
stained metaphases were captured by using the SD300-C SpectraCube and ana-
lyzed by using Skyview software. A total of 10–20metaphases were analyzed in
each tumor line.
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